Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal continuous positive airway pressure (nCPAP), the company said.
In August 2016, Windtree announced that it had received an initial $1 million from the grant, which is worth up to $2.6 million total. The Phase 2b trial was initated in 2015, and the FDA granted Fast Track Designation to Aerosurf in September 2016.
Windtree Therapeutics President and CEO Craig Fraser said, “We appreciate the NIH’s continued support of our Aerosurf Phase 2b RDS clinical trial. We believe that, with this award, the NIH has recognized the importance of our research and the potential for Aerosurf to transform the treatment of premature infants with RDS by enabling the administration of KL4 surfactant without invasive intubation and mechanical ventilation. We are pleased with our execution of the Aerosurf Phase 2b clinical trial and look forward to announcing top-line results from this study in July 2017.”
Read the Windtree Therapeutics press release.
